Light Hand Regulating Laboratory Developed Tests (LDTs)

Hello and welcome to the second half of the first Amplion company blog where I mapped out why our team is dedicated to seeing the promise of personalized medicine fully realized. So now I’m going to cover why we believe that 510(k)-style regulation of LDTs...

LDT Workshop Reveals New Insights

For those who were willing to listen through a lot of repetitive presentations during last week’s FDA workshop covering the Agency’s proposed regulation of LDTs, some interesting points were made by at least a few of the presenters and panelists. FDA...

LDT Regulation: The Plot Thickens

There have been some interesting developments over the last few weeks in the ongoing discussion about FDA’s desire to regulate LDTs. Pathologists Still Oppose Regulation At the annual meeting Nov. 12-14 of the Association for Molecular Pathology (AMP) a special...

New Revelations from Congressional Hearing on LDT Regulation

I finally had a chance to watch the complete Congressional hearing on LDT regulation that took place several weeks ago. Several interesting things came up which I haven’t seen mentioned anywhere else: – The issue of FDA’s authority to regulate LDTs...